Answers are grounded in this paper and cite their sources.
Systematic review and meta-analysis reveal increased cardiovascular events and mortality linked to chronic venous disease in adults, suggesting the need for targeted interventions.
Background/Introduction Chronic venous disease (CVeD) is a progressive condition that is highly prevalent especially in individuals with risk factors such as advanced age and obesity. It significantly impairs quality of life, with morbidity comparable to other chronic diseases. Epidemiological studies have suggested that CVeD may increase the risk of major adverse cardiovascular events (MACE) and mortality. This link may be driven by shared risk factors and overlapping pathophysiological mechanisms, including inflammation and endothelial dysfunction. Purpose We aimed at conducting a comprehensive systematic review and meta-analysis to gather evidence on the potential impact of CVeD on cardiovascular events and mortality in adults. Methods A systematic literature review was performed following the PRISMA guidelines, searching the PubMed database from inception until October 2025. The analysis included any retrospective or prospective studies, reporting cardiovascular event or mortality as study outcomes in patients diagnosed with CVeD. Risk of bias was assessed using the Newcastle-Ottawa scale. The primary outcomes were the occurrence of cardiovascular events (angina, atrial fibrillation, chronic heart failure, coronary artery disease, deep vein thrombosis, ischemic or hemorrhagic stroke, myocardial infarction, peripheral artery disease, pulmonary embolism, transient ischemic attack, or a composite of MACE) and all-cause mortality. Secondary outcomes were coronary artery and heart diseases. Meta-analyses of time-to-event outcomes were conducted pooling the hazard ratios (HR) with confidence interval (95% CI). Heterogeneity was assessed using the I² statistic. Results A total of 13 studies (6.4 million participants; 346,034 with CVeD) were included. Mean±SD age was 50.9±14.8 years, 54.6% of participants were female, and mean±SD body mass index was 23.8±3.2 kg/m2. The most frequent comorbidities were hypertension (35.8%), obesity (27.5%), hyperlipidaemia (26.4%), and chronic obstructive pulmonary disease (24.0%). The risk of bias was assessed as moderate and low in 2 and 11 studies, respectively. Meta-analysis of nine studies (321,020 participants) reported that CVeD significantly increased the overall risk of cardiovascular events (HR=1.5 [1.1;2.0], p=0.004). The risk of all-cause mortality was significantly increased, especially among patients with moderate to severe CVeD (five studies, 16,749 participants; HR=1.3 [1.2;1.6], p<0.001). Additionally, CVeD was associated with a higher risk of coronary and heart diseases (six studies, 81,254 participants; HR=1.3 [1.1;1.6], p=0.006). Heterogeneity level was high (I² ranging from 71% to 95%). Conclusion These findings suggest that patients with CVeD are at higher risk of cardiovascular events. This highlights the importance to systematically identifying patients with chronic venous disease who should benefit from appropriate treatment and risk assessment measures for cardiovascular prevention.
No takes yet. Share an insight, caveat, or question.
Luca et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: